New research backs CDY’s MK plan for osteoporosis
Cellmid (ASX:CDY) has received a boost with more academic research backing its midkine antibody’s potential in improving bone quality and fracture healing in osteoporosis models.
It told its shareholders today that a team of German researchers had found that MK antibodies could help in the healing of fractured bones in a validated model of osteoporosis in rodents – with the research published in journal PLoS One.
A previous study by the same researchers found that CDY’s MK antibody accelerated bone fracture healing in otherwise normal rodents.
Lead researcher Dr Astrid Liedert found that the application of CDY’s MK antibody in the rodent osteoporosis model improved the rate of fracture healing in both normal and osteoporotic animals.
The studies are still at a very early stage and any antibodies could still be a fair way off commercialisation – investors should consult a professional financial advisor before investing.
Dr Liedert also made the observation that the loss of bone mineral density and volume in otherwise intact but osteoporotic bones “some distance away” from the fracture site was reversed following the MK application.
The findings further cements CDY’s MK antibodies, which were found to accelerate bone healing in osteoporotic settings.
The upshot is that the MK antibodies could potentially be used by elderly patients with osteoporosis to help bone healing.
Osteoporotic patients have reduced bone regeneration capabilities, making bone healing especially difficult – and 30% of post-menopausal women suffer osteoporotic fractures after the age of 50.
Apart from the quality of life issues associated with fractures taking longer to heal, fractures can often cause severe and potentially life threatening complications for elderly patients.
The MK antibodies are under CDY’s subsidiary Lyramid, and CDY has filed patent applications covering the use of MK antibodies for fracture healing and restoring bone loss due to osteoporosis.
MK has been shown to be an important early marker for diagnosing various diseases and is only evident in a disease context. Unlike many other forms of treatment, targeting MK is not expected to harm normal health tissue.
While there are still hurdles to surmount before CDY and Lyramid can proceed to human trials, the further academic validation would be a boon to the company.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.